Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.
There is paucity of published data regarding controlled trials with risperidone and olanzapine in elderly psychotic patients. Medical records of 151 hospitalized geropsychiatric patients (risperidone patients n = 114 and olanzapine patients n = 37) were analyzed for demographic data, target symptoms, doses, effects, side effects, comorbid medical conditions and concurrent medications. The mean age of the patients was 71 years. The male: female ratio was essentially the same for both groups. The mean daily dose was 3 mg for risperidone and 10 mg for olanzapine. 78% of the risperidone group and 75% of the olanzapine group appear to have responded to treatment. The discontinuation rates of medication was the same in both groups (22%). Adverse events were reported in 16-17% in both groups. It appears from this study that both risperidone and olanzapine are relatively safe and effective in geropsychiatric patients with comorbid medical illnesses. Controlled studies and head-to-head comparison studies are recommended.
Madhusoodanan
S
S
Department of Psychiatry, St. John's Episcopal Hospital, Far Rockaway, New York 11691, USA.
Suresh
P
P
Brenner
R
R
Pillai
R
R
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015897:Comorbidity; D005260:Female; D005852:Geriatric Psychiatry; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D012189:Retrospective Studies; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D018967:Risperidone; D000077152:Olanzapine